Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Abstracts
Book Review
Case Report
Case Series
CMAS‡ - Pancreas - EUS-FNA Cytopathology (PSC guidelines) S1:1 of 5
CMAS‡ - Pancreas - EUS-FNA Cytopathology (PSC guidelines) S1:3 of 5
CMAS‡ - Pancreas - EUS-FNA Cytopathology (PSC guidelines) S1:4 of 5
CMAS‡ - Pancreas -Sampling Techniques for Cytopathology (PSC guidelines) S1:2 of 5
CMAS‡ - Pancreas- EUS-FNA Cytopathology (PSC guidelines) S1:5 of 5
Commentary
CytoJournal Monograph Related Review Series
CytoJournal Monograph Related Review Series (CMAS), Editorial
CytoJournal Monograph Related Review Series: Editorial
Cytojournal Quiz Case
Editorial
Erratum
Letter to Editor
Letter to the Editor
Letters to Editor
Methodology
Methodology Article
Methodology Articles
Original Article
Pap Smear Collection and Preparation: Key Points
Quiz Case
Research
Research Article
Review
Review Article
Systematic Review and Meta Analysis
View Point
View/Download PDF

Translate this page into:

Quiz Case
2023
:20;
35
doi:
10.25259/Cytojournal_37_2022

A rare and challenging case of uterine mass successfully reported in a cervical smear

Department of Laboratory Medicine and Pathology, The Royal Hospital, Muscat, Oman
Department of Radiology, The Royal Hospital, Muscat, Oman
Corresponding author: Dr. Waleed Al Amri, Department of Laboratory Medicine and Pathology, The Royal Hospital, Muscat, Oman. waleedsaid.alamri@moh.gov.om
Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Al Amri W, Al Salmi I, Al Nabhani SK, Al Hatrooshi BS. A rare and challenging case of uterine mass successfully reported in a cervical smear. CytoJournal 2023;20:35.

A 65-year-old postmenopausal woman, gravida 7 and para 5 from a rural hospital, presented with the lower abdominal pain associated with dysuria. A contrast-enhanced computed tomography was done, which showed a mass occupying the uterus and part of the mass is protruding into the upper vagina. A Papanicolaou (Pap) smear test was performed. The images are shown in [Figure 1].

Figure 1:
(a) Contrast-enhanced computed tomography scan axial image at the region of the pelvis showed a large heterogeneous enhancing mass occupying the uterus and protruding into the upper vagina (arrows). (b) Cytological cervical smears examination showed tissue fragments of round to oval hyperchromatic nuclei with scant cytoplasm in necrotic debris background (Pap, ×10). (c) Cells with abundant granular to glassy cytoplasm and nuclei with coarse irregularly distributed chromatin and macroprominent nucleoli (Pap, ×40). (d) Large bizarre cells with strap-like, rhabdoid morphology (Pap, ×20).

QUESTION

Q1. What is your diagnosis for the above findings?

  1. Squamous cell carcinoma.

  2. Endocervical adenocarcinoma

  3. Carcinosarcoma

  4. Neuroendocrine carcinoma.

The answer is (c).

Uterine carcinosarcoma, also known as malignant mixed Mullerian tumor (MMMT), is a rare and aggressive form of corpus uteri tumor. The tumor is composed of two cellular components: Epithelial and mesenchymal. The cervical smear findings showed both cellular components which raised the suspicion of carcinosarcoma. Endocervical adenocarcinoma can be a differential; however, the presence of large rhabdoid cells and tissue fragments of round to oval hyperchromatic nuclei with scant cytoplasm cells excluded adenocarcinoma. Squamous cell carcinoma (SCC) was excluded since the spindle cells that are present in this case look different from pleomorphic cells such as “tadpole” and “fiber” cells that are seen particularly in keratinizing type of SCC. Also, the lack of high-grade squamous intraepithelial lesion which did not favor the diagnosis of SCC. Hence altogether, the final report concluded that carcinosarcoma is the most likely correct diagnosis.

Further workup of the case

The patient underwent total hysterectomy with bilateral salpingo-oophorectomy and right and left lymph node. Gross examination of the resected specimen demonstrated a completely occupied endometrial cavity by a large polypoid soft tan mass. Furthermore, the mass extended through the cervix and protruded from the external cervical OS [Figure 2a]. Histopathological examination of the tumor mass revealed an admixture of spindle cells and epithelioid cells. The spindle cell component showed hyperchromatic pleomorphic nuclei and indistinct cell borders. It was admixed with varying proportions of large polygonal cells and strap-like cells. The epithelioid component was comprised of sheets of round cells with moderately hyperchromatic pleomorphic nuclei showing brisk mitosis and scattered spiral-like arterioles. Large areas of necrosis and hemorrhage were also seen. Additional sections of posterior uterine wall showed atrophic endometrium with irregular variably sized glands lined by columnar epithelial cells with marked nuclear atypia and prominent nucleoli [Figure 2b-d].

Figure 2:
(a) Gross examination of the total hysterectomy specimen showed a completely occupied endometrial cavity by a large polypoid soft tan mass attached to fundus, anterior and posterior wall and also extends through the cervix. (b) Histological sections of resected uterus showed sarcomatous area (H&E, ×4), (c) serous carcinoma (H&E, ×10), and (d) rhabdomyosarcomatous morphology (H&E, ×10).

ADDITIONAL QUIZ QUESTIONS

Q2. What are the following immunohistochemistry markers will be positive to confirm the diagnosis of carcinosarcoma?

  1. CD56, desmin, α-smooth muscle actin (SMA), MyoD-1, AE1/AE3, and tumor protein 53 (P53)

  2. Synaptophysin, chromogranin, and AE1/AE3

  3. CEA, vimentin, and ER

  4. P16, CK5/6, and P63

The answer is (a).

Immunohistochemical markers on sarcomatous components were positive for cluster of differentiation 56, and desmin and focal positivity for α-SMA and MyoD-1 [Figure 3a-d]. In the malignant epithelial components, AE1/AE3 and P53 showed positivity in more than 80% of the cells in keeping with serous carcinoma [Figure 3e].

Figure 3:
Immunohistochemical analysis of uterine carcinosarcoma. (a) The sarcomatous component showed positive for CD56 (×20), (b) Desmin (×10), and (c) partially positive α-Smooth Muscle Actin (α-SMA) muscle actin (×20), and (d) MyoD-1 (×40). (e) The carcinomatous component stained positive for P53 (×10).

Q3. All of following are heterologous component of carcinosarcoma, except for?

  1. Osteosarcomatous

  2. Liposarcomatous

  3. Angiosarcomatous

  4. Leiomyosarcoma

The answer is (d).

BRIEF REVIEW OF THE TOPIC

MMMT, also known as carcinosarcoma, is a rare and aggressive form of corpus uteri tumor. The tumor is composed of two cellular components: Epithelial and mesenchymal which commonly arise from the endometrial cavity.[1] Despite carcinosarcoma cases currently comprising <5% of all uterine tumors,[2] there is an evidence to suggest that there is an increase in the incidence of carcinosarcomas.[3] Hence, it becomes increasingly important for cytologists to be aware of the cytological features for diagnosing this form of tumor. Our cytological findings showed highly atypical epithelial and spindle cells, suggestive of a biphasic tumor type. In addition, a tumor diathesis is reported to be characteristic features of carcinosarcoma in cytological cervical smears.[4,5]

Our cytological features overlapped with previously described reports,[4-6] indicating that carcinosarcoma should always be considered in cases where malignant epithelial and spindly cells are found on a dirty background, especially in women presenting with postmenopausal bleeding.[7] In contrary, other studies have indicated that sarcomatous components are rare findings in cytological smears which make diagnosis of carcinosarcoma difficult.[6,8] A study by Hanley et al. showed that around 72.5% of carcinosarcoma patients had an abnormal Pap smear; however, the majority lacked cytological features consistent with a sarcomatous component.[9] In addition, a study showed that Pap smear test has low overall sensitivity (41.8%), but higher specificity (60.8%) for detecting uterine glandular lesions, which suggest that cytological findings should be confirmed by histological and immunochemical markers.[10]

Uterine carcinosarcoma is a malignancy of two components; epithelial (carcino-) and mesenchymal (-sarcoma), and it can be classified as homologous or heterologous types. The homologous type involves a sarcomatous component of intrauterus such as fibrosarcoma, endometrial stromal sarcoma, and leiomyosarcoma, whereas heterologous component involves cells of extrauterine connective tissues such as rhabdomyosarcoma and chondrosarcoma.[11] In the present case, the malignant epithelial components are positive for P53 and p16 in keeping with serous carcinoma. While the sarcomatous component with rhabdoid differentiation was positive for MyoD-1 and desmin and negative for h-caldesmon, demonstrating a heterologous uterine carcinosarcoma, consistent with previously reported case.[12]

This case was challenging since the Pap smear request was received from a peripheral hospital with limited clinical and radiological details. Furthermore, this tumor commonly occurs in postmenopausal women, with one of the most frequent clinical manifestations being postmenopausal bleeding. However, in this case, the patient presented with the lower abdominal pain and dysuria. Nevertheless, the presence of all the classic cytological features of carcinosarcoma enabled a successful diagnosis of this rare tumor in a Pap smear.

SUMMARY

Carcinosarcoma of the uterine wall may extend to cervix and present in cytological cervical (Pap) smears. Awareness of the possibility facilitates an optimal diagnosis and appropriate management.

Acknowledgment

The authors would like to express their thanks to Stacey Jones, MPharm, MBChB, MRCS, MD, for revising the manuscript.

COMPETING INTEREST STATEMENT BY ALL AUTHORS

The authors of this manuscript declare no conflicts of interest.

AUTHORSHIP STATEMENT BY ALL AUTHORS

WSAA planed, designed, collected data, and wrote the manuscript. BAH provided images, supervised, and edited the manuscript. SAS and SKAN provided images and revised the manuscript.

ETHICS STATEMENT BY ALL AUTHORS

Ethical approval was obtained from the institutional scientific research committee to publish this case report (SRC#CR14/2022).

LIST OF ABBREVIATIONS (In alphabetic order)

CD56 – Cluster of differentiation 56

CT – Computed tomography

MMMT – Malignant mixed Mullerian tumor

Pap – Papanicolaou

P53 or TP53 – Tumor protein 53

SMA – Smooth muscle actin

SCC – Squamous cell carcinoma

EDITORIAL/PEER-REVIEW STATEMENT

To ensure the integrity and highest quality of CytoJournal publications, the review process of this manuscript was conducted under a double-blind model (authors are blinded for reviewers and vice versa) through automatic online system.

References

  1. , , , , , , et al. Prognoses and prognostic factors of carcinosarcoma, endometrial stromal sarcoma and uterine leiomyosarcoma: A comparison with uterine endometrial adenocarcinoma. Oncology. 2006;71:333-40.
    [CrossRef] [PubMed] [Google Scholar]
  2. , , , , . Trends of uterine carcinosarcoma in the United States. J Gynecol Oncol. 2018;29:e22.
    [CrossRef] [PubMed] [Google Scholar]
  3. , , , , , , et al. Increasing incidence of uterine carcinosarcoma: A United States cancer statistics study. Gynecol Oncol Rep. 2022;40:100936.
    [CrossRef] [PubMed] [Google Scholar]
  4. , , . Cervicovaginal cytology in carcinosarcoma [malignant mixed mullerian (mesodermal) tumor] of the uterus. Diagn Cytopathol. 1992;8:33-40.
    [CrossRef] [PubMed] [Google Scholar]
  5. , , . Cervicovaginal (papanicolaou) smear findings in patients with malignant mixed müllerian tumors. Diagn Cytopathol. 2003;28:245-9.
    [CrossRef] [PubMed] [Google Scholar]
  6. , , . Eight cases of malignant mixed müllerian tumor (carcinosarcoma) of the uterus: Findings in SurePath™ cervical cytology. Diagn Cytopathol. 2014;42:165-9.
    [CrossRef] [PubMed] [Google Scholar]
  7. , , , . Malignant mixed müllerian tumor with an extensive squamous-cell carcinomatous component: A potential pitfall in liquid-based cervical cytology. Acta Cytol. 2014;58:413-8.
    [CrossRef] [PubMed] [Google Scholar]
  8. , , , . An abnormal cervicovaginal cytology smear in uterine carcinosarcoma is an adverse prognostic sign: Analysis of 25 cases. Am J Clin Pathol. 2004;122:434-9.
    [CrossRef] [PubMed] [Google Scholar]
  9. , , , , . Atypical findings on cervicovaginal smears correlate with cervical involvement by malignant mixed müllerian tumors of the uterus. Acta Cytol. 2015;59:319-24.
    [CrossRef] [PubMed] [Google Scholar]
  10. , , , , . Detecting uterine glandular lesions: Role of cervical cytology. Cytojournal. 2016;13:3.
    [CrossRef] [PubMed] [Google Scholar]
  11. , , , , . Carcinosarcoma of the uterus: A case report. Mol Clin Oncol. 2016;4:571-3.
    [CrossRef] [PubMed] [Google Scholar]
  12. . Liquid-based papanicolaou smear: Unusual cytological features of a uterine mass. Cytojournal. 2020;17:2.
    [CrossRef] [PubMed] [Google Scholar]
Show Sections